Home >Products> Reagents >Antibody> FGF-19 Recombinant Rabbit mAb (SDT-1070-17)
Reagents:  Molecular Biology   Biochemistry   Cell Biology   ELISA / Diagnostic Kits   Antibody   Serum/Medium   Other Reagents  
FGF-19 Recombinant Rabbit mAb (SDT-1070-17)
FGF-19 Recombinant Rabbit mAb (SDT-1070-17)
Place of Origin:
Singapore
Brand:
Starter
Model:
S0B2328-25μl
Price:
100
Hits:
Updated:
9/1/2025
  • Product Detail
  • Company Profile

    Product Specification


    HostRabbit
    AntigenFGF-19
    SynonymsFibroblast growth factor 19; FGF19
    ImmunogenRecombinant Protein
    LocationSecreted
    AccessionO95750
    Clone NumberSDT-1070-17
    Antibody TypeRecombinant mAb
    IsotypeIgG
    ApplicationWB, IHC-P, IP
    ReactivityHu
    PurificationProtein A
    Concentration0.5 mg/ml
    ConjugationUnconjugated
    Physical AppearanceLiquid
    Storage BufferPBS, 40% Glycerol, 0.05% BSA, 0.03% Proclin 300
    Stability & Storage

    12 months from date of receipt / reconstitution, -20 °C as supplied

    Dilution


    applicationdilutionspecies
    WB1:1000
    IHC1:100
    IP1:50

    Background

    FGF-19 is a member of the fibroblast growth factor (FGF) family. FGF family members possess broad mitogenic and cell survival activities, and are involved in a variety of biological processes including embryonic development cell growth, morphogenesis, tissue repair, tumor growth and invasion. This growth factor is a high affinity, heparin dependent ligand for FGFR4. FGF19 has important roles as a hormone produced in the ileum in response to bile acid absorption. Bile acids bind to the farnesoid X receptor (FXR), stimulating FGF19 transcription. FGF19 regulates new bile acid synthesis, acting through the FGFR4/Klotho-β receptor complexes in the liver to inhibit CYP7A1. FGF19 also has metabolic effects, affecting glucose and lipid metabolism when used in experimental mouse models. Furthermore, FGF19 is frequently amplified in human cancers. Amplification of the FGF19 genomic locus was found in liver cancer, breast cancer, lung cancer, prostate cancer, bladder cancer, and esophageal cancer, among others. Targeting FGF19 inhibits tumor growth in colon cancer cells and hepatocellar carcinoma. Increase in FGF19 correlates with tumor progression and poorer prognosis of hepatocellular carcinoma.

    bio-equip.cn
    AntBio is a biotechnology group company dedicated to serving life sciences, aiming to help scientists accelerate research and improve work efficiency. AntBio provides comprehensive and high-quality reagent tools for basic research, drug development, and diagnosis, including research grade antibodies, proteins, biochemical reagents, and assay kits. These research tools are widely used in different segments of life science research. The group company currently consists of three brands, Absin, Starter-Bio and UA-Bio.
Request Information
Request Information: yes no
Request Quotation: yes no
refresh

I agree to share my inquiry with the other matching suppliers.

Request Information

* Name:
Job Title:
* Tel:
Fax:
* E-mail:
Postcode:
Institution/Company:
Address:
* Country:
Request Information:
yes no
Request Quotation:
yes no
* Message:
* Verification Code:
refresh
I agree to share my inquiry to the other matching suppliers.